1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Lupus Erythematosus - Pipeline Review, H2 2013

Lupus Erythematosus - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Lupus Erythematosus - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Lupus Erythematosus - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Erythematosus. Lupus Erythematosus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lupus Erythematosus.
- A review of the Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lupus Erythematosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lupus Erythematosus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lupus Erythematosus - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lupus Erythematosus Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lupus Erythematosus 7
Lupus Erythematosus Therapeutics under Development by Companies 9
Early Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Lupus Erythematosus Therapeutics - Products under Development by Companies 12
Companies Involved in Lupus Erythematosus Therapeutics Development 13
AbGenomics International, Inc. 13
Isotechnika Pharma Inc. 14
Onyx Pharmaceuticals, Inc. 15
Farmacija d.o.o. Tuzla 16
Five Prime Therapeutics, Inc. 17
Theraclone Sciences, Inc. 18
Lupus Erythematosus - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Monoclonal Antibodies Targeting Interferon-alfa - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
ONX-0914 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
FPA-008 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
(metenkefalin + tridecactide) - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ND-2110 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
ND-2158 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
ND-346 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
P-13 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Lupus Erythematosus Therapeutics - Drug Profile Updates 35
Lupus Erythematosus Therapeutics - Dormant Products 37
Lupus Erythematosus - Product Development Milestones 38
Featured News and Press Releases 38
Oct 15, 2012: Idera Pharma Likely To Initiate Phase I Study Of Lupus Drug In Fourth Quarter Of 2012 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

Number of Products Under Development for Lupus Erythematosus, H2 2013 7
Products under Development for Lupus Erythematosus - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Clinical Stage Development, H2 2013 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
AbGenomics International, Inc., H2 2013 13
Isotechnika Pharma Inc., H2 2013 14
Onyx Pharmaceuticals, Inc., H2 2013 15
Farmacija d.o.o. Tuzla, H2 2013 16
Five Prime Therapeutics, Inc., H2 2013 17
Theraclone Sciences, Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Combination Products, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 24
Lupus Erythematosus Therapeutics - Drug Profile Updates 35
Lupus Erythematosus Therapeutics - Dormant Products 37



List of Figures

Number of Products under Development for Lupus Erythematosus, H2 2013 7
Products under Development for Lupus Erythematosus - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Early Clinical Stage Products, H2 2013 10
Discovery and Pre-Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 19
Assessment by Combination Products, H2 2013 20
Assessment by Route of Administration, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Molecule Type, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 24



Companies Mentioned

AbGenomics International, Inc.
Isotechnika Pharma Inc.
Onyx Pharmaceuticals, Inc.
Farmacija d.o.o. Tuzla
Five Prime Therapeutics, Inc.
Theraclone Sciences, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Potassium Voltage Gated Channel ...

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global ...

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 4 (CD49 Antigen Like Family ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.